Former Smoker Tells Of Losing Battle With Lung Cancer – Utah

As part of its adult cessation efforts within the Hispanic community, the Utah Department of Health‘s (UDOH) Tobacco Prevention and Control Program (TPCP) recently launched a series of TV spots that focus on the serious physical and emotional impact of tobacco on users and their families. The campaign features 59-year-old Gerardo Ozorio, a former smoker […]

What Is Mesothelioma? Lung Cancer From Asbestos

Mesothelioma is a from of lung cancer that is almost always caused by asbestos exposure and is most commonly found in the outer lining of the lungs called the mesothelium. A majority of the people who develop mesothelioma contract this cancer through breathing in asbestos fibers or being exposed to asbestos dust while on the […]

Asthma Risk Higher In Children Born By C-Section

Babies born via cesarean section are more likely to be asthmatic in comparison to babies delivered naturally, according to an article released on December 2, 2008 in Thorax, one of the BMJ Specialist journals. In the past decades, asthma rates have increased dramatically, paralleling an increase in cesarean section births. The proportion of these procedures […]

Childhood Eczema Still On The Increase In Developing Countries

Experts are warning policy makers that allergic disease might replace infectious disease as a major cause of ill health in cities undergoing rapid demographic changes in developing countries. New research tracking the number of cases of childhood eczema across the globe has revealed big changes in the prevalence of the condition over the last five […]

Columbia Center For Children’s Environmental Health Is 1 Of Only 3 Institutions To Receive Funds Through New NIH DISCOVER Progra

The Columbia Center for Children’s Environmental Health (CCCEH) at Columbia University’s Mailman School of Public Health, has received a $10.4 million grant from the National Institute of Environmental Health Sciences (NIEHS) to study environmental contributors to childhood asthma. The grant was awarded via a new NIEHS initiative called Disease Investigation through Specialized Clinically-Oriented Ventures in […]

New Drug Targets May Fight Tuberculosis, Bacterial Infections In Novel Way

Over the course of the 20th Century, doctors waged war against infectious bacterial illness with the best new weapon they had: antibiotics. But the emergence of dangerous, multi-drug resistant strains of tuberculosis and other killer infections means that in the 21st century antibiotics are losing ground against bacterial disease. Now, researchers from Weill Cornell Medical […]

Translational Research Patented First Experimental Treatment Against Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis is a disease with unknown cause with a very severe prognosis; when detected, it is already in an advanced stage. Patients suffering from it cannot develop with normality pulmonary gas exchange, and have a very reduced quality of life. Because of lack of an effective treatment, they rarely survive 5 years after […]

Recent Op-Ed Highlights Need To Pass Bill To Allow U.S. Residents To Purchase Health Insurance In Any State, Letter Says

A Dec. 12 Wall Street Journal opinion piece written by Merrill Matthews, executive director of the Council for Affordable Health Insurance, highlights the “tragedy of state governments forbidding citizens from exercising the basic right to buy health insurance from other states,” John Graham, director of health care studies at the Pacific Research Institute, writes in […]

Therapeutic Opportunities For Dry Powder Inhalation Accelerating – Greystone Associates Analyzes Technology And Therapeutic Factors

The convergence of socioeconomic and technology factors – the growing emphasis on drug self-administration for chronic conditions, the expected acceleration in protein- and peptide-based therapeutics, the availability of innovative inhaler device designs – is driving interest in pulmonary drug delivery technology and devices as an alternative to oral and parenteral routes of administration. A number […]

Alnylam Reports Continued Progress In Clinical Development Of ALN-RSV01 For The Treatment Of Respiratory Syncytial Virus (RSV) Infection

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced the presentation of results from its Phase I trial with ALN-RSV01 delivered via inhalation at the 18th Annual Drug Delivery to the Lungs meeting being held in Edinburgh, U.K. These data represent an important milestone in the company’s efforts to advance ALN-RSV01 as an […]